Suppr超能文献

水凝胶用于慢病毒基因传递。

Hydrogels for lentiviral gene delivery.

机构信息

Northwestern University, Department of Chemical & Biological Engineering, 2145 Sheridan Rd, Tech Building E-136, Evanston, IL 60208, USA.

出版信息

Expert Opin Drug Deliv. 2013 Apr;10(4):499-509. doi: 10.1517/17425247.2013.764864. Epub 2013 Jan 25.

Abstract

INTRODUCTION

Gene delivery from hydrogel biomaterials provides a fundamental tool for a variety of clinical applications including regenerative medicine, gene therapy for inherited disorders and drug delivery. The high water content and mild gelation conditions of hydrogels support their use for gene delivery by preserving activity of lentiviral vectors and acting to shield vectors from any host immune response.

AREAS COVERED

Strategies to control lentiviral entrapment within and retention/release from hydrogels are reviewed. The authors discuss the ability of hydrogel design parameters to control the transgene expression profile and the capacity of hydrogels to protect vectors from (and even modulate) the host immune response.

EXPERT OPINION

Delivery of genetic vectors from scaffolds provides a unique opportunity to capitalize on the potential synergy between the biomaterial design for cell processes and gene delivery. Hydrogel properties can be tuned to directly control the events that determine the tissue response to controlled gene delivery, which include the extent of cell infiltration, preservation of vector activity and vector retention. While some design parameters have been identified, numerous opportunities for investigation are available in order to develop a complete model relating the biomaterial properties and host response to gene delivery.

摘要

简介

水凝胶生物材料的基因传递为各种临床应用提供了一个基本工具,包括再生医学、遗传性疾病的基因治疗和药物输送。水凝胶的高含水量和温和的凝胶条件支持它们用于基因传递,因为它们可以保持慢病毒载体的活性,并防止载体受到任何宿主免疫反应的影响。

涵盖领域

本文综述了控制慢病毒在水凝胶内的包埋和保留/释放的策略。作者讨论了水凝胶设计参数控制转基因表达谱的能力,以及水凝胶保护载体免受(甚至调节)宿主免疫反应的能力。

专家意见

从支架输送遗传载体为利用细胞过程和基因传递之间的潜在协同作用提供了一个独特的机会。可以调整水凝胶的特性来直接控制决定组织对受控基因传递反应的事件,包括细胞浸润的程度、载体活性的保持和载体的保留。虽然已经确定了一些设计参数,但为了开发一个完整的模型,将生物材料特性和宿主对基因传递的反应联系起来,还有许多研究机会。

相似文献

1
Hydrogels for lentiviral gene delivery.
Expert Opin Drug Deliv. 2013 Apr;10(4):499-509. doi: 10.1517/17425247.2013.764864. Epub 2013 Jan 25.
2
Lentivirus immobilization to nanoparticles for enhanced and localized delivery from hydrogels.
Mol Ther. 2010 Apr;18(4):700-6. doi: 10.1038/mt.2009.300. Epub 2010 Jan 5.
3
Fibrin hydrogels for lentiviral gene delivery in vitro and in vivo.
J Control Release. 2012 Jan 10;157(1):80-5. doi: 10.1016/j.jconrel.2011.08.036. Epub 2011 Sep 1.
4
Injectable alginate hydrogel for enhanced spatiotemporal control of lentivector delivery in murine skeletal muscle.
J Control Release. 2016 Sep 10;237:42-9. doi: 10.1016/j.jconrel.2016.06.047. Epub 2016 Jul 1.
5
Toward Tightly Tuned Gene Expression Following Lentiviral Vector Transduction.
Viruses. 2020 Dec 11;12(12):1427. doi: 10.3390/v12121427.
6
Localized lentivirus delivery via peptide interactions.
Biotechnol Bioeng. 2016 Sep;113(9):2033-40. doi: 10.1002/bit.25961. Epub 2016 Mar 6.
7
Advances in lentiviral vectors: a patent review.
Recent Pat DNA Gene Seq. 2012 Aug;6(2):82-90. doi: 10.2174/187221512801327433.
8
Immune responses to lentiviral vectors.
Curr Gene Ther. 2007 Oct;7(5):306-15. doi: 10.2174/156652307782151515.
9
Applications of lentiviral vectors in molecular imaging.
Front Biosci (Landmark Ed). 2014 Jun 1;19(6):835-53. doi: 10.2741/4251.
10
Non-viral vector delivery from PEG-hyaluronic acid hydrogels.
J Control Release. 2007 Jul 31;120(3):233-41. doi: 10.1016/j.jconrel.2007.04.015. Epub 2007 May 1.

引用本文的文献

1
2
Intelligent Hydrogel-Assisted Hepatocellular Carcinoma Therapy.
Research (Wash D C). 2024 Oct 14;7:0477. doi: 10.34133/research.0477. eCollection 2024.
4
Recombinant Porcine Interferon-α Decreases Pseudorabies Virus Infection.
Vaccines (Basel). 2023 Oct 12;11(10):1587. doi: 10.3390/vaccines11101587.
6
Designing electrospun fiber platforms for efficient delivery of genetic material and genome editing tools.
Adv Drug Deliv Rev. 2022 Apr;183:114161. doi: 10.1016/j.addr.2022.114161. Epub 2022 Feb 17.
7
Lentiviral Vectors Delivered with Biomaterials as Therapeutics for Spinal Cord Injury.
Cells. 2021 Aug 16;10(8):2102. doi: 10.3390/cells10082102.
8
Injectable, macroporous scaffolds for delivery of therapeutic genes to the injured spinal cord.
APL Bioeng. 2021 Mar 9;5(1):016104. doi: 10.1063/5.0035291. eCollection 2021 Mar.
9
Injectable BMP-2 gene-activated scaffold for the repair of cranial bone defect in mice.
Stem Cells Transl Med. 2020 Dec;9(12):1631-1642. doi: 10.1002/sctm.19-0315. Epub 2020 Aug 12.
10
Adhesive thermosensitive gels for local delivery of viral vectors.
Biotechnol Bioeng. 2019 Sep;116(9):2353-2363. doi: 10.1002/bit.27007. Epub 2019 May 20.

本文引用的文献

1
Biomaterial Scaffolds for Controlled, Localized Gene Delivery of Regenerative Factors.
Adv Wound Care (New Rochelle). 2013 Apr;2(3):100-106. doi: 10.1089/wound.2011.0325.
2
Clinical applications of retinal gene therapy.
Prog Retin Eye Res. 2013 Jan;32:22-47. doi: 10.1016/j.preteyeres.2012.09.001. Epub 2012 Sep 17.
3
Hydrogel macroporosity and the prolongation of transgene expression and the enhancement of angiogenesis.
Biomaterials. 2012 Oct;33(30):7412-21. doi: 10.1016/j.biomaterials.2012.06.081. Epub 2012 Jul 15.
4
Lentiviral vectors: basic to translational.
Biochem J. 2012 May 1;443(3):603-18. doi: 10.1042/BJ20120146.
5
Enhanced adenovirus transduction of hMSCs using 3D hydrogel cell carriers.
Mol Biotechnol. 2013 Feb;53(2):207-16. doi: 10.1007/s12033-012-9522-y.
7
Hydrogels to modulate lentivirus delivery in vivo from microporous tissue engineering scaffolds.
Drug Deliv Transl Res. 2011 Feb 1;1(1):91-101. doi: 10.1007/s13346-010-0011-1.
8
Adenovirus-associated virus vector-mediated gene transfer in hemophilia B.
N Engl J Med. 2011 Dec 22;365(25):2357-65. doi: 10.1056/NEJMoa1108046. Epub 2011 Dec 10.
9
Multifunctional, multichannel bridges that deliver neurotrophin encoding lentivirus for regeneration following spinal cord injury.
Biomaterials. 2012 Feb;33(5):1618-26. doi: 10.1016/j.biomaterials.2011.11.002. Epub 2011 Nov 29.
10
Phase 1 gene therapy for Duchenne muscular dystrophy using a translational optimized AAV vector.
Mol Ther. 2012 Feb;20(2):443-55. doi: 10.1038/mt.2011.237. Epub 2011 Nov 8.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验